期刊
ONCOLOGY LETTERS
卷 26, 期 2, 页码 -出版社
SPANDIDOS PUBL LTD
DOI: 10.3892/ol.2023.13950
关键词
CD47; single nucleotide polymorphism; non-small-cell lung cancer; immune checkpoint inhibitors; nivolumab
类别
This study investigated the association between CD47 gene polymorphisms and the therapeutic effect of nivolumab in patients with NSCLC. The results showed that the G/G genotype of CD47 polymorphisms was significantly associated with longer progression-free survival and overall survival. Therefore, CD47 gene polymorphisms may serve as a novel predictive biomarker for nivolumab efficacy in advanced NSCLC patients.
Immune checkpoint inhibitors (ICIs), such as nivolumab, play an essential role in non-small-cell lung cancer (NSCLC) treatment. Programmed death ligand-1 has been used as a predictive biomarker for the efficacy of ICI treatment in patients with NSCLC; however, its predictive value is considered insufficient. Therefore, there is an urgent need for better predictive biomarkers. The present study focused on the CD47 molecule, which is associated with macrophages and tumor immunity. The study aimed to investigate the association between CD47 single nucleotide polymorphism (SNP) and the therapeutic effect of nivolumab in patients with NSCLC. The CD47 SNP genotypes and clinical outcomes were retrospectively analyzed in 164 patients with NSCLC treated with nivolumab at Kyoto University Hospital (Kyoto, Japan). Patients with the G/G genotype of the CD47 SNP rs3804639 had significantly longer progression-free survival than those with the G/T or T/T genotypes [2.6 months vs. 2.1 months, hazard ratio (HR), 0.70; P=0.026]. Moreover, the G/G genotype of the CD47 SNP rs3804639 was associated with a significantly longer median overall survival than the G/T or T/T genotypes of the CD47 SNP rs3804639 (24.8 months vs. 12.0 months, HR, 0.64; P=0.021). In conclusion, CD47 polymorphism may be a novel predictive biomarker of nivolumab efficacy in patients with advanced NSCLC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据